1Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
Clin Appl Thromb Hemost. 2013 Sep;19(5):557-61. doi: 10.1177/1076029612443305. Epub 2012 Apr 11.
To investigate the efficacy of recombinant human soluble thrombomodulin (rTM) in disseminated intravascular coagulation (DIC) associated with severe postpartum hemorrhage (PPH).
We conducted a retrospective review of 36 patients with severe PPH complicated by DIC admitted to a single tertiary center. The first 26 patients were treated without rTM (control group), and the next 10 consecutive patients were treated with rTM. Clinical parameters including bleeding symptoms and coagulation indices were evaluated.
Baseline characteristics, total blood loss, and transfusion requirements were similar between the 2 groups. On day 2, there was a significant difference between the 2 groups in the decrease in d-dimer level from baseline. The incidence of bleeding symptoms was decreased in the rTM group compared with the control group. No adverse events were observed in the rTM group.
Recombinant human thrombomodulin may be an effective adjunctive therapy in the management of DIC related to PPH.
研究重组人可溶性血栓调节蛋白(rTM)在与严重产后出血(PPH)相关的弥漫性血管内凝血(DIC)中的疗效。
我们对单中心收治的 36 例严重 PPH 合并 DIC 患者进行了回顾性研究。前 26 例患者未接受 rTM 治疗(对照组),接下来的 10 例连续患者接受 rTM 治疗。评估了包括出血症状和凝血指标在内的临床参数。
两组患者的基线特征、总失血量和输血需求相似。第 2 天,两组间从基线水平下降的 d-二聚体水平有显著差异。rTM 组的出血症状发生率较对照组降低。rTM 组未观察到不良反应。
重组人血栓调节蛋白可能是治疗与 PPH 相关的 DIC 的有效辅助治疗方法。